Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia

被引：12

作者：

Chan, Kico ^{[1
]}

Elsum, Imogen ^{[1
]}

Gold, Judy ^{[1
,2
]}

Layton, Chloe ^{[1
,3
]}

Accadia, Lisa ^{[1
,3
]}

Bryant, Mellissa ^{[1
,3
]}

Gunn, Jack ^{[1
]}

Djordjevic, Filip ^{[1
,4
]}

Purcell, Isabelle ^{[5
]}

Dicka, Jane ^{[6
]}

Forrest, Martin ^{[5
]}

Crawford, Sione ^{[6
]}

Hellard, Margaret ^{[1
,2
,3
,7
,8
]}

Pedrana, Alisa ^{[1
]}

机构：

[1] Burnet Inst, Dis Eliminat, Melbourne, Vic, Australia

[2] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia

[3] Alfred & Monash Univ, Dept Infect Dis, Melbourne, Vic, Australia

[4] Burnet Inst, Behav & Hlth Risks, Melbourne, Vic, Australia

[5] Hepatitis Victoria LiverWELL, Melbourne, Vic, Australia

[6] Harm Reduct Victoria, Melbourne, Vic, Australia

[7] Univ Melbourne, Doherty Inst, Melbourne, Vic, Australia

[8] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia

来源：

JOURNAL OF VIRAL HEPATITIS | 2021年 / 28卷 / 03期

基金：

英国医学研究理事会;

关键词：

HCV infection; health promotion; Hepatitis C; incentives; people who inject drugs;

D O I：

10.1111/jvh.13447

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：569 / 572

页数：4

共 8 条

[1]

[Anonymous], 2018, Statement of Principles Regarding Hepatitis C

[2] Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy [J].

Das, Debasis ;

Pandya, Mayank .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2018, 18 (07) :584-596

[3] Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review [J].

Degenhardt, Louisa ;

Peacock, Amy ;

Colledge, Samantha ;

Leung, Janni ;

Grebely, Jason ;

Vickerman, Peter ;

Stone, Jack ;

Cunningham, Evan B. ;

Trickey, Adam ;

Dumchev, Kostyantyn ;

Lynskey, Michael ;

Griffiths, Paul ;

Mattick, Richard P. ;

Hickman, Matthew ;

Larney, Sarah .

LANCET GLOBAL HEALTH, 2017, 5 (12) :E1192-E1207

[4] Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia [J].

Doyle, Joseph S. ;

Scott, Nick ;

Sacks-Davis, Rachel ;

Pedrana, Alisa E. ;

Thompson, Alexander J. ;

Hellard, Margaret E. ;

Dietze, Paul ;

McBryde, Emma ;

Sievert, William ;

Stoove, Mark ;

Higgs, Peter ;

Petrie, Denis ;

Vickerman, Peter .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (09) :1223-1229

[5] Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis [J].

Khatun, Mousumi ;

Ray, Ratna B. .

CELLS, 2019, 8 (10)

[6] Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? [J].

Madden, Annie ;

Hopwood, Max ;

Neale, Joanne ;

Treloar, Carla .

PLOS ONE, 2018, 13 (11)

[7] Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs [J].

Wade, Amanda J. ;

Doyle, Joseph S. ;

Gane, Edward ;

Stedman, Catherine ;

Draper, Bridget ;

Iser, David ;

Roberts, Stuart K. ;

Kemp, William ;

Petrie, Dennis ;

Scott, Nick ;

Higgs, Peter ;

Agius, Paul A. ;

Roney, Janine ;

Stothers, Lisa ;

Thompson, Alexander J. ;

Hellard, Margaret E. .

CLINICAL INFECTIOUS DISEASES, 2020, 70 (09) :1900-1906

[8]

WHO, 2016, GLOBAL HLTH SECTOR S

← 1 →